The up to $818 million deal between Locus Biosciences and Janssen Pharmaceuticals (a division of Johnson & Johnson) that was announced yesterday points toward a new path for CRISPR gene editing technologies and (potentially) the whole field of microbiome-targeted therapies. Based in Research Triangle Park, N.C., Locus is commercializing research initially developed by scientists at […]
View More Up to $818 million deal between J&J and Locus Biosciences points to a new path for CRISPR therapiesKnowledge is POWER